Compare Harley-Davidson Inc (HOG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Harley-Davidson Inc trades at $28.1 (market cap $2.93B), while Regeneron Pharmaceuticals Inc trades at $671.32 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 24.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| HOG | REGN | |
|---|---|---|
Market Cap | $2.93B | $70.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $812.27 |
52-Week Low | $17.19 | $545.46 |
Enterprise Value | $3.32B | $64.42B |
Dividend Yield | 2.64% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $27.85, up 4.78% today, with a bullish technical signal from moving averages and a neutral RSI near 69. Recent earnings show mixed results, with Q1 2026 missing estimates, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. The company is executing a turnaround strategy, including cost cuts and bringing Revolution Max engine production back to the U.S., amid positive retail sales growth in Q1 2026.
The outlook is cautious; while valuation ratios like P/E of 13.77 and P/B of 0.91 appear attractive, declining revenue and net income margins pose risks. Analyst consensus is mostly Hold (65.71%), with a price target of $23.40 below the current price, indicating skepticism about near-term growth despite operational initiatives.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
